Novo Nordisk CEO Lars Jorgensen, who led company into weight loss drugs, to step down
Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by "mutual agreement" with the company's board of directors, citing "recent market challenges" and a steep decline in the company's share price.
Lars Fruergaard Jorgensen's departure comes a week after the company downgraded its sales and profits forecast, and follows a more than 50% decline in the company's shares since mid-2024.
The company said May 7 that Wegovy sales in the U.S. had been undercut by cheaper replica drugs produced by so-called compounding pharmacies using active ingredients of patented drugs. They are relied on as substitutes when name-brand drugs aren't available. The Food and Drug Administration, however, has said however that shortages have eased and the replicas will have to cease in the coming months.
On Sunday, a study published in the New England Journal of Medicine showed that people lost more weight using Wegovy competitor Zepbound, made by pharmaceutical company Eli Lilly. Eli Lilly funded the study. Novo Nordisk's share price is down 54% from its peak in June 2024. Its U.S.-listed shares fell another 3% in premarket trading Friday.
The company, headquartered in Bagsvaerd, Denmark, praised Jorgensen has having led Novo Nordisk through a "significant growth journey and transformation" during his eight-year tenure as CEO.
"The changes are, however, made in light of the recent market challenges Novo Nordisk has been facing, and the development of the company's share price since mid-2024," the company said in a statement. The board and Jorgensen "have jointly concluded that initiating a CEO succession is in the best interest of the company and its shareholders."
Jorgensen will continue as CEO "for a period" to support a smooth transition.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
22 minutes ago
- New York Post
Weight loss drugs like Ozempic could mess with your birth control — and get you pregnant
A UK watchdog is urging women on GLP-1 weight-loss drugs like Ozempic and Mounjaro to use effective forms of birth control after receiving more than 40 pregnancy-related reports linked to the medications. The warning comes as women flood social media with stories of their so-called 'Ozempic babies' — including surprise pregnancies while on the pill. Trying to shed pounds, not grow a baby bump? Here's what you need to know about GLP-1s, pregnancy and the best contraception options to stay protected. 4 Studies show that at least one in eight US adults have tried GLP-1s. íÅí°íâ¬í¸í½í° íâíµí¼íµíËí°í¾ – What's in your GLP-1? Several GLP-1 drugs dominate the market, including Ozempic and Wegovy. Both contain semaglutide, an active ingredient that mimics a natural hormone in the body that boosts insulin production, slows digestion and curbs appetite. Then there's Saxenda and Victoza, powered by liraglutide, which functions in a similar way. Newer drugs like Mounjaro and Zepbound rely on tirzepatide, a key ingredient that targets a second hormone involved in appetite and blood sugar control. A surprise side effect While gastrointestinal symptoms like nausea, vomiting and diarrhea are common with GLP-1s, the surprise side effect making waves is unexpected pregnancy. The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has received 28 reports related to pregnancy in patients on tirzepatide, and nine each for semaglutide and liraglutide. 4 Women on tirzepatide-based GLP-1s should use barrier contraception. nenetus – In an alert this week, the agency warned that tirzepatide may reduce the effectiveness of oral contraceptives, especially in women with higher body weight. As a result, it recommended using barrier methods like condoms while on drugs like Mounjaro. So far, there's no evidence that GLP-1s affect non-oral birth control like IUDs, implants, patches, or rings, according to the UK's Faculty of Reproductive Healthcare. And yes, the advice applies even to women previously told they were infertile. GLP-1s have been shown to boost fertility by aiding weight loss, reducing inflammation and improving insulin sensitivity — leading some to conceive just months after starting treatment. 4 GLP-1 agonists can increase your fertility, but they can also interfere with pregnancy. Louis-Photo – Can you take GLP-1s while pregnant? Experts say no — at least not yet. There's not enough data to confirm whether GLP-1s are safe during pregnancy. While a some human studies suggests there is no harm in first-trimester use, testing in animals has shown the drugs could increase the risk of miscarriage and birth defects. 4 Scientists are still working to understand whether GLP-1s can negatively impact a developing fetus. Evrymmnt – Another reason to skip GLP-1s while pregnant: they suppress your appetite and can trigger gastrointestinal issues, which may lead to nutrient deficiencies that impact fetal development. The drugs should also be avoided during breastfeeding, since there's not enough research to confirm safety for infants. Trying to conceive? Here's the timeline If you're planning to get pregnant, the MHRA recommended stopping GLP-1s before you start trying to conceive and giving your body time to clear the drugs. For semaglutide users, that means quitting at least two months ahead. If you're on tirzepatide, stop one month before trying. Liraglutide clears the system faster, so you can stop right before you start trying to conceive.
Yahoo
2 hours ago
- Yahoo
Newcastle Hit Back at ‘Saudi Tax' Transfer Demands
Summer Strategy Built on Realism, Not Riches There's a perception Newcastle United are flush with cash, a perception the club believes is both outdated and damaging. As Luke Edwards revealed in his excellent report for Telegraph Sport, Newcastle are 'growing increasingly frustrated by rival clubs putting a 'Saudi tax' on transfers and refuse to be held to ransom over key targets.' Advertisement It's an accusation that's been hanging in the air since the PIF-led takeover in 2021. The expectation is that Newcastle will, and should, spend extravagantly – but the club is pushing back, constrained by the Premier League's strict profit and sustainability rules (PSR). Edwards was given rare insight into the club's negotiating table, and what's clear is that Newcastle are walking a tightrope. They are attempting to add quality to Eddie Howe's squad without blowing apart the financial structure that's slowly, carefully, been built. Value Takes Priority Over Vanity Newcastle's business so far has been quiet, but deliberate. There's clarity in their strategy. They want to recruit in four key positions – goalkeeper, centre-back, right-sided forward, and striker – but they 'cannot spend upwards of £60 million on players when wages are also a consideration.' That's where the Bryan Mbeumo situation becomes telling. As Edwards explains, Mbeumo was 'a leading target by Newcastle's recruitment team' but wage demands and a hefty transfer fee forced the club to walk away. Signing the Brentford man could have meant making him the top earner at the club. Doing so before star striker Alexander Isak is rewarded with a new contract – talks for which are set to begin in July – would be a recipe for dressing room unrest. Advertisement And so, Newcastle hold firm. No player, however talented, is worth tearing up the wage structure for. 'Mbeumo would have likely been Newcastle's highest earner if he had signed,' Edwards wrote. 'That would have inevitably prompted others at the club to ask for parity.' Photo: IMAGO Talent Targets Still in Sight – But on Newcastle's Terms The ambition hasn't waned, but the method is clear. Newcastle have eyes on several exciting players. Burnley's James Trafford remains a top goalkeeping target, while Bournemouth's Antoine Semenyo and Nottingham Forest's Anthony Elanga are being considered for that right-sided role. However, progress is limited – so far – by inflated price tags. Advertisement Brighton's Joao Pedro fits the mould of what Newcastle are after: young, versatile, and Premier League-proven. Yet his price – reportedly up to £70 million – risks consuming a huge chunk of the budget. It's a fee Newcastle could theoretically pay, but not if they want to fill all four positions. As Edwards reports, 'it has caused pause for thought internally.' Eintracht Frankfurt's Hugo Ekitike has long been admired, but the £80 million fee means any move is unlikely unless things change. Likewise, Crystal Palace's Marc Guehi remains of interest in central defence, but Newcastle will wait for his value to drop, knowing his contract is entering its final year. Contract Talks with Isak Key to Summer Stability Everything this summer revolves around Alexander Isak. Newcastle are planning to make him the club's highest earner – a just reward for his performances and potential. But the negotiations won't be easy, and the club knows that bringing in players on higher wages before that deal is done could be destabilising. Advertisement 'Bringing in new players on significantly more money than that before those talks begin is fraught with danger,' Edwards warns. It's a point of sensitivity at St James' Park – one that highlights Newcastle's desire to build a sustainable elite club rather than simply buy one. The Magpies are still shopping in the upper tiers of the market, but they're doing so with calculation, not chaos. Other potential names include James McAtee, liked by Howe and potentially available at £25 million. West Ham's Mohammed Kudus is another admired target, though his future may hinge on finding the right financial compromise. As ever, there will be quiet moves, too. 'Some of their biggest transfers, like Bruno Guimaraes from Lyon and Sandro Tonali from AC Milan, were only known about 48 hours before they signed,' Edwards notes. Newcastle haven't stopped moving – they've just learned to move smartly.
Bloomberg
2 hours ago
- Bloomberg
Don't Count on a Sustained Fed-ECB Decoupling, Schnabel Says
It would be wrong to expect a persistent policy divergence between the US Federal Reserve and the European Central Bank, according to Executive Board member Isabel Schnabel. 'I expect this trade conflict to play out as a global shock that's working for both global demand and supply — we can discuss which of the two effects on inflation is larger because that that determines the net effect,' the German central banker said on Saturday.
